View Rule

View EO 12866 Meetings Printer-Friendly Version     Download RIN Data in XML

TREAS/IRS RIN: 1545-BM26 Publication ID: Fall 2016 
Title: Branded Prescription Drug Fee 
Abstract:

This proposed regulation modifies the definition or the term "controlled group" in 26 CFR 51.2T.

 
Agency: Department of the Treasury(TREAS)  Priority: Substantive, Nonsignificant 
RIN Status: Previously published in the Unified Agenda Agenda Stage of Rulemaking: Final Rule Stage 
Major: No  Unfunded Mandates: No 
EO 13771 Designation: uncollected 
CFR Citation: 26 CFR 51   
Legal Authority: 26 U.S.C. 7805    26 U.S.C. 9008    Pub. L. 111-347    Affordable Care Act   
Legal Deadline:  None
Timetable:
Action Date FR Cite
NPRM  07/28/2014  79 FR 43699   
NPRM Comment Period End  10/27/2014 
Interim Final Rule  03/00/2017 
Additional Information: REG-123286-14 Drafting attorney: Celia Gabrysh (202) 317-6855 Reviewing attorney: Charles Langley (202) 317-6855 Treasury attorney: CC: PSI
Regulatory Flexibility Analysis Required: No  Government Levels Affected: Undetermined 
Small Entities Affected: No  Federalism: No 
Included in the Regulatory Plan: No 
RIN Data Printed in the FR: No 
Related RINs: Related to 1545-BM27 
Agency Contact:
Celia Gabrysh
Attorney-Advisor (Tax)
Department of the Treasury
Internal Revenue Service
1111 Constitution Avenue NW., Room 5309,
Washington, DC 20224
Phone:202 317-6855
Fax:202 317-6733
Email: celia.gabrysh@irscounsel.treas.gov